Mandate

Vinge is advising Xspray Pharma in connection with its rights issue of units

Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.

Xspray Pharma AB (publ) is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård NevonenLinnéa Sellström and Adrian Filipovic.

 

Related

Vinge has advised Aspira Partners on the establishment of Aspira Fund I

Vinge has advised Aspira Partners ("Aspira") on the establishment and fundraising of Aspira's inaugural blind-pool fund, Aspira Fund I (D) AB and Aspira Fund I (E) AB (collectively, "Fund I" or the "Fund").
August 31, 2026

Vinge advises Consolid Equity on the sale of Road Mobility Services to Nalka

Vinge has advised Consolid Equity on the sale of Road Mobility Services to Nalka. In connection with the transaction, Consolid, entrepreneurs and management will reinvest and remain as minority shareholders alongside Nalka as the new majority shareholder.
August 28, 2026

Vinge advises IK Partners and Selatek in connection with the acquisition of Jamo Sikring

Vinge advises IK Partners and their portfolio company Selatek AB ("Selatek") in connection with the acquisition of JAMO SIKRING A/S ("Jamo Sikring"), a Danish specialist in the installation, maintenance and ongoing inspection of fire protection systems. The acquisition marks Selatek's establishment of operations in Denmark and strengthens the group's position in fire safety and security services in the Nordics.
August 21, 2026